Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Detroit |
| State: |
|
Michigan |
| Zip Code: |
|
48201 |
| Conditions: |
|
Prostate Cancer |
| Purpose: |
|
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory
may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine
samples from patients with prostate cancer and healthy volunteers.
|
| Study Summary: |
|
OBJECTIVES:
- To identify a potential novel marker of prostate cancer in the blood and urine,
11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection
of early relapse in patients previously treated for early-stage prostate cancer.
OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary
11-dh-TXB2 levels by HPLC and tandem-mass spectrometry.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Meets one of the following criteria:
- Histopathologically confirmed prostate cancer meeting 1 of the following
criteria:
- Newly diagnosed untreated disease
- Received prior local therapy (prostatectomy, definitive radiotherapy,
brachytherapy, or cryotherapy) with no evidence of disease activity
(defined as serum PSA < 0.4 ng/mL post therapy) and by imaging studies
- Experienced biochemical failure (defined as rise in serum PSA ≥ 0.4 ng/mL
post therapy)
- Healthy volunteer (clinic patient with no history of clinically significant
malignancies within the past 6 months)
PATIENT CHARACTERISTICS:
- No clinical evidence of liver cirrhosis or chronic liver disease (i.e., evidence of
ascites or severe coagulopathy)
- No active prostatitis
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 30 days since prior and no concurrent regular antiplatelet agents
(including aspirin, anagrelide, cilastazole, clopidogrel, dipyridamole,
pentoxiphylline, sulfinpyrazone, or ticlopidine)
- More than 7 days since prior and no concurrent NSAIDs (including ibuprofen,
celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin,
ketoprofen, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin,
piroxicam, sulindac, or tolmetin)
|
| NCT ID: |
|
NCT00984919 |
| Primary Contact: |
|
Principal Investigator
Elisabeth I. Heath, MD
Barbara Ann Karmanos Cancer Institute
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Detroit, Michigan 48201
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|